Current and emerging topical therapies for atopic dermatitis

Area of Science:

• Dermatology
• Immunology
• Pharmacology

Background:

• Atopic dermatitis (AD) pathogenesis involves epidermal barrier dysfunction and T helper cell type 2 (Th2) inflammation.
• Key cytokines like IL-4 and IL-13 drive B cell immunoglobulin E production, leading to atopic disease.
• Current AD therapies target the Th2 cellular pathway, including PDE-4 inhibitors, receptor antagonists, and JAK inhibitors.

Purpose of the Study:

• To review current and emerging topical treatments for atopic dermatitis (AD).
• To summarize clinical evidence, safety, and efficacy profiles of novel AD therapies.
• To highlight recent advancements and the importance of staying current with evolving treatment strategies.

Main Methods:

• Review of clinical evidence for topical AD treatments.
• Summary of safety and efficacy data from clinical trials.
• Focus on novel therapies, including phosphodiesterase 4 (PDE-4) inhibitors like Crisaborole.

Main Results:

• Recent completion of Phase III clinical trials for Crisaborole, a novel PDE-4 inhibitor.
• Emerging therapies demonstrate advancements in targeting the Th2 pathway in AD.
• Clinical evidence supports the use of current and novel topical treatments for AD.

Conclusions:

• Staying updated on evolving AD therapies is crucial for dermatologists.
• Novel treatments offer improved patient care and advancement in the field.
• Crisaborole represents a significant development in topical AD treatment options.